| Recruiting | Refractory Advanced diGestive Neuroendocrine Carcinomas Treated With tARlatamab Advanced Neuroendocrine Carcinomas of The Digestive System, Advanced Neuroendocrine Carcinomas Unknown Primary Origin | Phase 2 | 2025-12-18 |
| Recruiting | Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocri Grade1-2 Advanced Midgut Neuroendocrine Tumors (NETs) | Phase 3 | 2025-06-12 |
| Completed | Retrospective Analysis of the Experience With Larotrectinib in Patients With Solid Neoplasms With NTRK Fusion Solid Neoplasms With NTRK Fusions | — | 2025-02-11 |
| Recruiting | Sacituzumab govitEcan in THYroid Cancers Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer | Phase 2 | 2024-09-13 |
| Recruiting | Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tu Neuroendocrine Tumors, Lung Neuroendocrine Neoplasm, Thymus Neoplasms | Phase 3 | 2023-10-27 |
| Active Not Recruiting | Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer. Differentiated Thyroid Cancer | Phase 2 | 2023-05-25 |
| Completed | Nutrition in Gastroenteropancreatic Neuroendocrine Tumor Gastroenteropancreatic Neuroendocrine Tumor | — | 2021-02-24 |
| Completed | Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CAB Neuroendocrine Tumor, Anaplastic Thyroid Cancer, Adenocarcinoma | Phase 2 | 2020-10-07 |
| Completed | Platinum-doublet Chemotherapy and Nivolumab for the Treatment of Subjects With Neuroendocrine Neoplasms (NENs) Neuroendocrine Tumors, Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Tumor | Phase 2 | 2019-10-11 |
| Recruiting | GETNE Registration of Thyroid Cancer Thyroid Cancer | — | 2019-05-28 |
| Terminated | Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carci Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma, Metastatic Thyroid Cancer | Phase 2 | 2019-04-02 |
| Completed | Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lun Neuroendocrine Tumors, Neuroendocrine Neoplasm of Lung | Phase 2 | 2017-04-11 |
| Completed | Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Suni Pancreatic Neuroendocrine Tumour Metastatic | Phase 2 | 2017-02-14 |
| Completed | Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors Neuroendocrine Tumors | Phase 2 | 2015-10-01 |
| Completed | Radiological Response of Pancreatic Neuroendocrine Tumors: Comparison Between the Choi and the RECIST Criteria Pancreatic Neuroendocrine Tumors | — | 2015-07-24 |
| Completed | A Study to Assess the Safety and the Efficacy of the Combination of TH-302 and Sunitinib in Neuroendocrine Pan Neuroendocrine Tumors, Pancreatic Neoplasms | Phase 2 | 2015-05-11 |
| Completed | A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated M Pancreatic Neuroendocrine Cancer | Phase 2 | 2015-05-01 |
| Completed | Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor Neuroendocrine Tumors | Phase 3 | 2014-10-27 |
| Unknown | Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Ca Neuroendocrine Tumors, Advanced Cancer | Phase 2 / Phase 3 | 2011-11-01 |
| Completed | Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET Gastrointestinal Neoplasms | Phase 2 | 2011-06-08 |
| Completed | Pazopanib as Single Agent in Advanced NETs Advanced/Metastatic Neuroendocrine Tumors | Phase 2 | 2011-01-26 |